Sarepta Therapeutics (NASDAQ: SRPT) presented preclinical data at the 22nd Annual Meeting of the Oligonucleotide Therapeutics Society showing that its ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

FDA